Bioavailability in Pharmacokinetics – Complete Notes with A2G Memory Tricks & MCQs
By Arvind Sharma, B.Pharm, M.Pharm, Assistant Professor, MUIT
Bioavailability in Pharmacokinetics: A Masterclass for Pharmacy Students
Welcome to this high-yield masterclass on Bioavailability, a critical concept in Pharmacokinetics for all aspiring pharmacists. Understanding bioavailability is key to drug development, dosage regimen design, and therapeutic outcomes. This module is designed to be conceptual, exam-oriented, and revision-friendly for GPAT, NExT, RRB, and DSSSB exams.
Introduction to Bioavailability
Bioavailability (F) is defined as the fraction (or percentage) of an administered dose of unchanged drug that reaches the systemic circulation. In simpler terms, it's how much and how fast a drug gets to its site of action after being given by any route other than intravenous (IV) administration.
A drug administered intravenously (IV) is considered to have 100% bioavailability (F=1 or 100%) because it directly enters the systemic circulation without undergoing absorption barriers or first-pass metabolism.
Absolute Bioavailability (Fabs)
Absolute bioavailability compares the bioavailability of a drug administered by an extravascular route (e.g., oral, intramuscular, subcutaneous) to the bioavailability of the same drug administered intravenously (IV). It provides a measure of how efficiently the drug is absorbed and avoids first-pass metabolism compared to direct systemic delivery.
Formula for Absolute Bioavailability:
Fabs = (AUCoral × DoseIV) / (AUCIV × Doseoral)
Where:
- AUCoral: Area Under the Curve for oral administration.
- DoseIV: Intravenous dose administered.
- AUCIV: Area Under the Curve for intravenous administration.
- Doseoral: Oral dose administered.
Explanation: AUC represents the total drug exposure over time. By comparing AUCs adjusted for dose, we can determine the fraction of the extravascular dose that reached systemic circulation relative to an IV dose.
Relative Bioavailability (Frel)
Relative bioavailability compares the bioavailability of a drug from one extravascular formulation (e.g., a test formulation) to another extravascular formulation (e.g., a standard or reference formulation) of the same drug. This is commonly used in bioequivalence studies to compare generic drugs with brand-name drugs.
Formula for Relative Bioavailability:
Frel = (AUCtest × Dosestandard) / (AUCstandard × Dosetest)
Where:
- AUCtest: Area Under the Curve for the test formulation.
- Dosestandard: Dose of the standard formulation.
- AUCstandard: Area Under the Curve for the standard/reference formulation.
- Dosetest: Dose of the test formulation.
Explanation: This formula helps to assess if two different formulations (e.g., different manufacturers, different excipients) deliver the same amount of active drug to the systemic circulation. When doses are equal, it simplifies to the ratio of AUCs.
Factors Affecting Bioavailability
1. Drug Solubility & Dissolution Rate
Highly soluble drugs dissolve faster. Poorly soluble drugs (e.g., Griseofulvin) may have limited bioavailability.
2. Lipid Solubility
Highly lipid-soluble drugs (e.g., Diazepam) cross membranes easily. Very low/high lipid solubility can be problematic.
3. Chemical Instability
Drugs unstable in gastric pH (e.g., Penicillin G, Insulin) or destroyed by enzymes (e.g., L-Dopa) have low oral bioavailability.
4. Particle Size
Smaller particle size generally increases dissolution rate and surface area, enhancing absorption.
5. First-Pass Metabolism (Presystemic Elimination)
Extensive metabolism by the liver or gut wall before reaching systemic circulation (e.g., Propranolol, Lidocaine, Morphine, Salbutamol).
6. Gastric Emptying Rate
Faster emptying can increase absorption of drugs absorbed in the intestine. Slower emptying can delay absorption or expose acid-labile drugs to degradation.
7. Intestinal Motility
Rapid transit time (diarrhea) can reduce contact time for absorption. Slow transit time can lead to degradation or increased absorption for some.
8. pH at Absorption Site
Ionization status affects absorption. Weak acids absorbed better in acidic stomach, weak bases in alkaline intestine.
9. Food-Drug Interactions
Food can increase (e.g., Griseofulvin with fatty meal), decrease (e.g., Tetracyclines with milk), or have no effect on absorption.
10. Drug Formulations (Excipients, Coatings)
Differences in binders, disintegrants, coatings (e.g., enteric coatings for acid-labile drugs) can significantly impact dissolution and absorption.
11. Disease States
Conditions like Crohn's disease, celiac disease, liver cirrhosis can alter absorption and first-pass metabolism.
12. Drug Interactions
Co-administration of drugs can alter GI motility, pH, or enzyme activity, affecting absorption of other drugs.
Clinical Relevance of Bioavailability
Understanding bioavailability is crucial for effective pharmacotherapy.
1. Dose Adjustment
Drugs with low oral bioavailability (e.g., Propranolol, F ~25-30%) often require higher oral doses compared to IV doses to achieve the same systemic concentration.
2. Route of Administration Selection
For drugs with very poor oral bioavailability or extensive first-pass metabolism (e.g., Lidocaine, Insulin), non-oral routes (IV, IM, SC) are preferred.
3. Bioequivalence Studies
Regulatory agencies require generic drugs to demonstrate bioequivalence to brand-name drugs. This ensures that the generic formulation delivers the drug to the systemic circulation at the same rate and extent as the innovator product (i.e., similar F, Tmax, Cmax).
4. Therapeutic Drug Monitoring (TDM)
For drugs with narrow therapeutic indices (e.g., Digoxin, Phenytoin), variations in bioavailability can lead to sub-therapeutic or toxic effects. TDM helps individualize dosing.
5. Food Interactions
Knowing how food affects bioavailability helps provide patient counseling (e.g., Griseofulvin with fatty meal for increased absorption, Tetracycline on empty stomach).
Quick Revision: Bioavailability Concepts
| Feature | Absolute Bioavailability (Fabs) | Relative Bioavailability (Frel) |
|---|---|---|
| Reference Route | Intravenous (IV) | Another extravascular route/formulation (e.g., standard oral) |
| Purpose | Determines the fraction of drug reaching systemic circulation from an extravascular route. | Compares bioavailability of two different extravascular formulations (e.g., generic vs. brand). |
| Maximum Value | 1 (or 100%) for IV dose, <1 for extravascular. | Can be >1, <1, or =1 depending on the comparison. |
| Key Use | Drug development, understanding systemic drug exposure potential. | Bioequivalence studies, formulation comparison. |
| Example | Oral Propranolol Fabs is ~25%. | Generic A's Frel to Brand X is 0.98. |
Journey of an Oral Drug: A Vertical Flow Chart
Visualize the path a drug takes after oral administration to reach systemic circulation.
1. Oral Administration
Drug taken by mouth.
2. Disintegration & Dissolution
Tablet/capsule breaks down, drug dissolves into GI fluids.
3. Absorption
Drug moves from GI tract into portal circulation (e.g., intestine).
4. First-Pass Metabolism
Drug passes through liver, some metabolized before reaching systemic circulation.
5. Systemic Circulation
Unchanged drug reaches target sites.
A2G Mnemonic for Bioavailability (FARM)
Here's a simple mnemonic to recall key aspects of bioavailability, especially useful for exam quick recall:
F - Fraction of unchanged drug reaching systemic circulation.
A - AUC is proportional to absorbed dose (assuming linear kinetics).
R - Routes: IV has 100% F; Oral F is usually <100%.
M - Metabolism: First-pass metabolism is a major reason for low oral F.
High-Yield Exam Points & PYQ Focus
Definition of Bioavailability: Often asked in 2-mark questions. Remember
Explore More Pharmacokinetics Topics
Test Your Knowledge: Bioavailability MCQs
Attempt these multiple-choice questions to test your understanding of bioavailability.